Evaluating Endostatin Plus TC Regimen in Secondary Malignant Neoplasm of Liver Using Contrast Enhancement Ultrasonography

Inclusion Criteria: * Histologic diagnosis of nasopharyngeal carcinoma or NSCLC * With an evaluable secondary malignant neoplasm of Liver, diameter≥2cm * Without transcatheter arterial chemoembolization (TACE) treatment * Performance status of 0 to 1 on the Eastern Cooperative Oncology Group (ECOG) Scale. * Estimated life expectancy of at least 3 months * Patient compliance and geographic proximity that allow adequate follow-up. * Adequate organ function including the following: Bone marrow: absolute neutrophil count (ANC) \>or= 1.5x10\^9/L, platelets \>or= 100x10\^9/L, hemoglobin \>or= 9g/dL. Hepatic: bilirubin \<1.5 x ULN, alkaline phosphatase, aspartate transaminase (AST) and alanine transaminase (ALT) \< 2.5 x ULN (alkaline phosphatase, AST, ALT \< 5 x ULN is acceptable if liver has tumor involvement). Renal: calculated creatinine clearance \> 45 ml/min. * Men or women of at least 18 years of age. * Signed informed consent from patient. Exclusion Criteria: * Women who are pregnant or in lactation * Systemic treatment for another cancer within the year prior to study entry * Known hypersensitivity to any of the study drugs or to drugs with similar chemical structures * Use of investigational agents within 28 days of the Baseline visit, or participating simultaneously in any other clinical studies * Severe co-morbidity of any type that may interfere with assessment of the patient for the study